- Exchange: NASDAQ CM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for TrovaGene Inc (TROV)
| Open: | 5.9200 | Day's Range: | 5.8300 - 6.6900 | Volume: | 111,275 |
|---|---|---|---|---|---|
| Previous Close: | 6.6900 | 52wk Range: | 2.0900 - 8.9600 | 1-Yr Rtn: | +12.63% |
Key Statistics for TROV
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.8300 |
| Est. EPS (USD) (12/2013) | -0.4400 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 104.47 |
| Shares Outstanding (M) | 15.62 |
| 30 Day Average Volume | 87,023 |
| Price/Book (mrq) | 47.7419 |
| Price/Sale (ttm) | 180.3277 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/14/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for TROV
Company Profile & Key Executives for TROV
TrovaGene, Inc. is an applied genomics company. The Company is developing a non-invasive testing technology using transrenal nucleic acid (TrNA) markers for infectious diseases, prenatal testing, early detection of cancer, and monitoring of organ and cell transplantation.
| Antonius P Schuh "Tony"Chief Executive Officer | Stephen L Zaniboni "Steve"Chief Financial Officer |
| Mark ErlanderChief Scientific Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
TROV News
-
Industry News
No stories found
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page